PTX3 and colorectal carcinoma: In 2016, two studies simultaneously reported that upregulated postsurgical serum PTX3 was linked to CRC relapse (90, 91), and a subsequent cohort study confirmed the prognostic value of PTX3 as an independent indicator of poor prognosis in CRC patients following surgery (92).